Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing

References

1. 1.↵
   1. Game F.,
   2. Hinchliffe R.,
   3. Apelqvist J.,
   4. Armstrong D.,
   5. Bakker K.,
   6. Hartemann A.,
   7. Löndahl M.,
   8. Price P.,
   9. Jeffcoate W.

   , A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab. Res. Rev. 2012, 28, 119–141.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Berlanga J.,
   2. Fernández J. I.,
   3. López E.,
   4. López P. A.,
   5. Río A. d.,
   6. Valenzuela C.,
   7. Baldomero J.,
   8. Muzio V.,
   9. Raíces M.,
   10. Silva R.

   , Heberprot-P: a novel product for treating advanced diabetic foot ulcer. MEDICC review 2013, 15, 11–15.

   OpenUrl
3. 3.↵
   1. López-Saura P.,
   2. Yera-Alos I.,
   3. Valenzuela-Silva C.,
   4. González-Díaz O.

   , Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic Foot Ulcers. Adv. Pharmacoepidem. Drug Safety 2013, 2, 2167–1052.

   OpenUrl
4. 4.↵
   1. Besada V.,
   2. Antuch W.,
   3. Cinza A.,
   4. Rojas I.,
   5. Quintana M.,
   6. Padron G.,
   7. Takao T.,
   8. Shimonishi Y.

   , Chemical characterization of recombinant human epidermal growth factor. Anal. Chim. Acta 1990, 239, 301–305.

   OpenUrl
5. 5.↵
   1. Santana H.,
   2. González Y.,
   3. Campana P.,
   4. Noda J.,
   5. Amarantes O.,
   6. Itry R.,
   7. Beldarraín A.,
   8. Páez R.

   , Screening for stability and compatibility conditions of recombinant human Epidermal Growth Factor for parenteral formulation: effect of pH, buffers, and excipients. Int. J. Pharm. 2013, 452, 52–62.

   OpenUrlPubMed
6. 6.↵
   1. Cini J.,
   2. Ace C.,
   3. Spaltro J.,
   4. Georgenascimento C.

   In Photooxidation of recombinant human epidermal growth-factor, The FASEB Journal, 1992; Federation Amer Soc Exp Biol 9650 Rockville Pike, Bethesda, MD 20814-3998: 1992; pp A1350–A1350.
7. 7.↵
   1. Senderoff R.,
   2. Wootton S.,
   3. Boctor A.,
   4. Chen T.,
   5. Giordani A.,
   6. Julian T.,
   7. Radebaugh G.

   , Aqueous stability of human epidermal growth factor 1-48. Pharm. Res. 1994, 11, 1712–1721.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Parti R.,
   2. Ardosa J.,
   3. Yang L.,
   4. Mankarious S.

   , In vitro stability of recombinant human factor VIII (RecombinateTM). Haemophilia 2000, 6, 513–522.

   OpenUrlPubMed
9. 9.↵
   1. Santana H.,
   2. Sotolongo J.,
   3. González Y.,
   4. Hernández G.,
   5. Chinea G.,
   6. Gerónimo H.,
   7. Amarantes O.,
   8. Beldarraín A.,
   9. Páez R.

   , Stabilization of a recombinant human epidermal growth factor parenteral formulation through freeze-drying. Biologicals 2014, http://dx.doi.org/10.1016/j.biologicals.2014.07.005.
10. 10.↵
    Q1A(R2), International Conference on Harmonisation, Stability Testing of New Drug Substances and Products. 2003.
11. 11.↵
    Q3A(R2), International Conference on Harmonisation, Impurities in new drug substances. 2006.
12. 12.↵
    Q6A, International Conference on Harmonisation, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and Products: Chemical Substances. 1999.
13. 13.↵
    Q6B, International Conference on Harmonisation, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. 1999.
14. 14.↵
    1. Manning M.,
    2. Chou D.,
    3. Murphy B.,
    4. Payne R.,
    5. Katayama D.

    , Stability of protein pharmaceuticals: an update. Pharm. Res. 2010, 27, 544–575.

    OpenUrlCrossRefPubMed
15. 15.↵
    Q1B, International Conference on Harmonisation, Photostability Testing of New Drug Substances and Products. 1996.
16. 16.↵
    Q5C, International Conference on Harmonisation, Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. 1996.
17. 17.↵
    Q1E, International Conference on Harmonisation, Evaluation for Stability Data. 2003.
18. 18.↵
    1. Bradford M.

    , A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Chem. 1976, 72, 248–254.

    OpenUrl
19. 19.↵
    1. Vázquez J.,
    2. Freyre M.,
    3. Duarte C.,
    4. Ferra E.,
    5. López I.,
    6. Pérez E.,
    7. Gavilondo J.

    , Radio y enzimoinmunoensayos para el Factor de Crecimiento Epidérmico con anticuerpos monoclonales de ratón. Biotecnol. Apl. 1990, 7, 42–49.

    OpenUrl
20. 20.↵
    1. Mire-Sluis A. R.,
    2. Gerrard T.,
    3. Das R. G.,
    4. Padilla A.,
    5. Thorpe R.

    , Biological assays: Their role in the development and quality control of recombinant biological medicinal products. Biologicals 1996, 24, 351–362.

    OpenUrlPubMed
21. 21.↵
    1. Finney D.

    , Statistical Method in Biology Assay. Griffin: London, 1978.
22. 22.↵
    1. Ejima D.,
    2. Yumioka R.,
    3. Arakawa T.,
    4. Tsumoto K.

    , Arginine as an effective additive in gel permeation chromatography. J. Chromatogr. A 2005, 1094, 49–55.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Schägger H.,
    2. vonJagow G.

    , Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1-100 kDa. Anal. Biochem. 1987, 166, 368–379.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    <71> Sterility test, 2008. USP/NF. Ed. Rockville, MD: United States Pharmacopoeial Convention.
25. 25.↵
    British Pharmacopoeia, 1998. London, UK.
26. 26.↵
    1. Sanford B.,
    2. Bon C.

    , Pharmaceutical Statistics Practical and Clinical Applications. In Third ed.; Marcel Dekker, Inc.: 1997; pp 315–325.
27. 27.↵
    1. Chirino A.,
    2. Mire-Sluis A.

    , Characterizing biological products and assessing comparability following manufacturing changes. Nat. Biotechnol. 2004, 22, 1383–1391.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Freyre F.,
    2. Vázquez J.,
    3. Duarte C.,
    4. Ferrá E.,
    5. López I.,
    6. Arteaga N.

    , Anticuerpos monoclonales que reconocen los factores de crecimiento epidérmico humano y murino. Interferón y Biotecnología 1989, 6, 32–46.

    OpenUrl
29. 29.↵
    1. Puchades Y.,
    2. Ojalvo A.,
    3. García Y.,
    4. Chinea G.,
    5. Gerónimo H.,
    6. Vispo N.

    , Identification of peptides mimicking the natural epitope recognized by the CB-EGF1 anti-EGF monoclonal antibody. Biotecnol. Apl. 2005, 22, 203–206.

    OpenUrl
30. 30.↵
    1. Kerwin B. A.,
    2. Remmele R. L.

    , Protect from light: photodegradation and protein biologics. J Pharm. Sci. 2007, 96, 1468–1479.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Lu H.-S.,
    2. Chai J.-J.,
    3. Li M.,
    4. Huang B.-R.,
    5. He C.-H.,
    6. Bi R.-C.

    , Crystal structure of human epidermal growth factor and its dimerization. J Biol. Chem. 2001, 276, 34913–34917.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Oliva A.,
    2. Llabrés M.,
    3. Fariña J. B.

    , Data analysis of kinetic modelling used in drug stability studies: isothermal versus nonisothermal assays. Pharm. Res. 2006, 23, 2595–2602.

    OpenUrlPubMed
33. 33.↵
    1. Wakankar A.,
    2. Borchardt R.

    , Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J. Pharm. Sci 2006, 95, 2321–2336.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Lai M. C.,
    2. Topp E. M.

    , Solid-state chemical stability of proteins and peptides. J. Pharm. Sci. 1999, 88, 489–500.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Yoshioka S.,
    2. Aso Y.

    , Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals. J. Pharm. Sci. 2007, 96, 960–981.

    OpenUrlCrossRefPubMedWeb of Science
36. 36.↵
    1. Yoshioka S.,
    2. Aso Y.

    , A quantitative assessment of the significance of molecular mobility as a determinant for the stability of lyophilized insulin formulations. Pharm. Res. 2005, 22, 1358–1364.

    OpenUrlPubMed
37. 37.↵
    Q1D, International Conference on Harmonisation, Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products. 2003.
38. 38.↵
    1. Vromans H.,
    2. Van Laarhoven J.

    , A study on water permeation through rubber closures of injection vials. Int. J. Pharm. 1992, 79, 301–308.

    OpenUrl
39. 39.↵
    1. Corveleyn S.,
    2. De Smedt S.,
    3. Remon J. P.

    , Moisture absorption and desorption of different rubber lyophilisation closures. Int. J. Pharm. 1997, 159, 57–65.

    OpenUrl
40. 40.↵
    1. Araki F.,
    2. Nakamura H.,
    3. Nojima N.,
    4. Tsukumo K.,
    5. Sakamoto S.

    , Stability of recombinant epidermal growth factor in various solutions. Chem. Pharm. Bull. 1989, 37, 404–407.

    OpenUrlCrossRefPubMed
41. 41.↵
    1. Schultz G. S.,
    2. Gibson D. J.

    , Measurement of Biomarkers for Impaired Healing in Fluids and Tissues. In Measurements in Wound Healing, Springer: 2013; pp 243–258.
42. 42.↵
    1. Avis K. E.,
    2. Lieberman H. A.,
    3. Lachmann L

    . Pharmaceutical Dosage Forms: Parenteral Medications. Marcel Dekker, Inc., New York. 1993; Vol. 2
43. 43.↵
    1. Fernandez-Montequín J.,
    2. Valenzuela-Silva C.,
    3. Díaz O. G.,
    4. Savigne W.,
    5. Sancho-Soutelo N.,
    6. Rivero-Fernández F.,
    7. Sánchez-Penton P.,
    8. Morejón-Vega L.,
    9. Artaza-Sanz H.,
    10. García-Herrera A.,
    11. González-Benavides C.,
    12. Hernández-Cañete C.,
    13. Vázquez-Proenza A.,
    14. Berlanga-Acosta J.,
    15. López-Saura P.

    , Intralesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: Multicenter, randomized, placebo-controlled, double-blind study. Int. Wound J. 2009, 6, 432–444.

    OpenUrlCrossRefPubMedWeb of Science
44. 44.↵
    1. Kinnunen H. M.,
    2. Mrsny R. J.

    , Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site. J. Control. Rel. 2014, 182, 22–32.

    OpenUrlCrossRefPubMed
45. 45.↵
    1. Debye P.,
    2. Hückel E.

    , De la theorie des electrolytes. I. abaissement du point de congelation et phenomenes associes. Physikalische Zeitschrift 1923, 24, 185–206.

    OpenUrlWeb of Science